arrow
T

Till Sprenger

University of Ottawa
H指数:56
被引数:1.2万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Long-term safety and efficacy of ponesimod, an oral S1P1 receptor modulator, in relapsing-remitting multiple sclerosis (RRMS): Results from randomized phase 2b core and extension studies spanning up to 13 years

富马酸非那司提(ponesimod)在复发缓解型多发性硬化(RRMS)中的长期安全性和有效性:来自为期长达13年的随机Ⅱb期CORRE和扩展研究的成果

2026-08-010
PRE
Long-term safety and efficacy of ponesimod in participants with relapsing multiple sclerosis: results from the phase 3 OPTIMUM 5-year long term extension study

富马酸博纳利司(ponesimod)在复发型多发性硬化患者中的长期安全性与有效性:来自OPTIMUM 3期研究5年长期扩展研究的结果

2026-03-250
OAAI
Ponesimod as add-on treatment in patients with active relapsing multiple sclerosis under dimethyl fumarate (POINT): A phase 3, randomized, placebo-controlled clinical trial

Ponesimod作为添加治疗在活动性复发多发性硬化患者中的应用(POINT):一项III期、随机、安慰剂对照临床试验

2025-07-130
PRE
Visual evoked potentials in multiple sclerosis: P100 latency and visual pathway damage including the lateral geniculate nucleus

多发性硬化症的视觉诱发电位: P100潜伏期和视觉通路损伤,包括外侧膝状核

2024-05-011
OAAI
Optical coherence tomography versus other biomarkers: Associations with physical and cognitive disability in multiple sclerosis

光学相干断层扫描与其他生物标志物的比较: 多发性硬化患者身体和认知功能障碍的相关性

2023-09-293
OAAI
Anterior horn atrophy in the cervical spinal cord: A new biomarker in progressive multiple sclerosis

颈脊髓前角萎缩: 进行性多发性硬化症的新生物标志物

2022-12-225
PRE
Advancing our commitment to our peer reviewers

推进我们对同行评审员的承诺

2021-10-133
PREAI